12th March 2015: Basilea Pharmaceutica Ltd. has recently reported that the U.S. Food and Drug Administration (FDA) approved Astellas’ New Drug Application (NDA) for the use of isavuconazole for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients. Basilea’s partner Astellas will market the drug as CRESEMBA® (isavuconazonium sulfate) in the United States.
Deputy Managing Partner of TranScrip, Dr. Marcin Mankowski said “TranScrip have been a long standing clinical and regulatory partner to Basilea and we are delighted to see the latest successful approval. It is an important development for the medical community, fulfilling an unmet medical need and offering a new option for the treatment of severely ill patients at risk of fungal infections with high morbidity and mortality.“
To view the full details of the original Basilea news release please click here.